Cyclacel Pharmaceuticals Inc Share Price Nasdaq
Equities
US23254L3069
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
05-14 | Cyclacel Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
05-14 | Transcript : Cyclacel Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 14, 2024 |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 3.19M 251M |
---|---|---|---|---|---|
Net income 2024 * | -11M -865M | Net income 2025 * | -19M -1.49B | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.3
x | P/E ratio 2025 * |
-0.39
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 76.14% |
Latest transcript on Cyclacel Pharmaceuticals Inc
Managers | Title | Age | Since |
---|---|---|---|
Spiro Rombotis
CEO | Chief Executive Officer | 65 | 31/07/97 |
Paul McBarron
DFI | Director of Finance/CFO | 63 | 31/12/01 |
Brian Schwartz
CTO | Chief Tech/Sci/R&D Officer | 52 | 16/12/20 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 83 | 28/02/06 | |
Brian Schwartz
CTO | Chief Tech/Sci/R&D Officer | 52 | 16/12/20 |
Spiro Rombotis
CEO | Chief Executive Officer | 65 | 31/07/97 |
1st Jan change | Capi. | |
---|---|---|
+9.58% | 115B | |
+12.41% | 107B | |
-3.52% | 21.6B | |
-12.38% | 22.31B | |
-6.87% | 19.19B | |
-3.35% | 18.23B | |
-38.57% | 17.62B | |
+7.51% | 14.26B | |
+35.67% | 12.37B |